-gliptin
A DPP-4 inhibitor: keeps the body's own GLP-1 active longer. Used in type 2 diabetes.
- Drugs ending in -gliptin: 18
- Approved somewhere: 7
- With a US drug page: 1
Approved and clinical-stage drugs in ChEMBL whose names ending in -gliptin, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Linagliptin | Approved | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Alogliptin | Approved | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Evogliptin | Approved | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Saxagliptin anhydrous | Approved | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Sitagliptin | Approved | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Teneligliptin | Approved | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Vildagliptin | Approved | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Anagliptin | Phase 3 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Dutogliptin | Phase 3 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Gemigliptin | Phase 3 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Gosogliptin | Phase 3 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Omarigliptin | Phase 3 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Retagliptin | Phase 3 | — | — |
| Trelagliptin | Phase 3 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Besigliptin | Phase 2 | — | — |
| Bisegliptin | Phase 2 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Carmegliptin | Phase 2 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Denagliptin | Phase 2 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO